NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.
Genital HPV genotypes are generally distinct serotypes, but whether variants within a genotype can represent serologic subtypes is unclear. In this study we used serum from human volunteers vaccinated with HPV16 L1 VLPs from variant 114K, to examine cross-neutralization of variants from each of the five major phylogenetic branches of HPV16. Recombinant Semliki Forest virus-derived pseudovirions for each variant were generated and combined with serum from vaccines, and the mixture was monitored for infectivity in a standard C127 cell focal transformation assay. Sera from all 10 VLP-immunized individuals had neutralizing activity against each of the variant pseudovirions. For each of the sera, variant titers differed by only fourfold or less from the median titer. Therefore, from a vaccine perspective, HPV16 variants belong to a single serotype. Vaccination with HPV16 114K L1 VLPs generates antibodies that should confer a similar degree of protection against all known phylogenetic branches of HPV16.
Pastrana
D V
DV
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, 20892, USA.
Vass
W C
WC
Lowy
D R
DR
Schiller
J T
JT
D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D003429:Cross Reactions; D006801:Humans; D007114:Immunization; D009500:Neutralization Tests; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control; D010802:Phylogeny; D012703:Serotyping; D014412:Tumor Virus Infections / Q000517:prevention & control; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014771:Virion / Q000276:immunology* / Q000378:metabolism; D019065:Virus Assembly
D000914:Antibodies, Viral; D014765:Viral Vaccines